Generic Biosimilar Medicines Association

Making Medicines Affordable

  • Home
  • About GBMA
    • Contact us
    • GBMA Members
    • Guiding principles
    • Code of Practice
      • Code Complaint Committee
      • Event Reporting
        • Educational Events
        • Non-Price Benefit Reports
      • Annual Review
        • 2011
        • 2012
        • 2013
        • 2014
        • 2015
        • 2016
        • 2017
        • 2018
        • 2019
        • 2020
      • Lodging a complaint
    • Media Enquiries
    • Our Objectives
    • Links
  • Advocacy
    • Extended Strategic Agreement
    • Generic Medicines Working Group (GMWG)
    • Submissions
  • Generics
    • Facts and Fallacies
    • Key Figures on Generic Medicines
    • What is a Generic Medicine?
    • Bioequivalence Explained
  • Biosimilars
    • IGBA Global Biosimilars Week
    • GBMA Position on Biosimilars
      • Impact of Biosimilars
      • Switching
      • Pharmacy Substitution
      • Regulation
      • Awareness and Uptake
      • Naming
    • Key Figures on Biosimilars
  • Topics
    • IGBA
    • Price Disclosure
    • Intellectual Property
    • International Trade Agreements
  • News
    • News 2021
    • News 2020
    • News 2019
    • News 2018
    • News 2017
    • News 2016
    • News 2015
    • News 2014
  • GBMA Education
  • COVID-19 Virus
    • COVID-19 Virus: The Facts
You are here: Home / Biosimilars / GBMA Position on Biosimilars / Impact of Biosimilars

Impact of Biosimilars

Biosimilars are like generic medicines in their ability to reduce healthcare costs and increase patient access to life changing medicines

  • The relatively new but growing class of biologic medicines brings significant clinical improvement to patients, especially in the area of cancer. The term “biologics” most often refers to therapeutic proteins manufactured by recombinant technologies and include, for example, growth hormone, insulin, erythropoietin and antibodies. In contrast to chemical molecules, biologics are much bigger, more complicated to produce, have certain immunogenicity concerns and display a generally higher variability since they are produced by living cells.
  • Like all medicines, biologics have a time-limited patent protection and once exclusivity expires, other companies can produce follow-on versions with the promise of lower costs to the health care system and increased patient access to these life changing medicines.
  • For biologics, these are called “biosimilars” and correspond in principle with generics for chemical medicines – with one major difference. While generics can be 100% identical to the original molecule, this cannot be proven with biosimilars as ALL biologics include an inherent amount of variability. This can be the result of batch-to-batch variability, as well as manufacturing changes, among others. Biosimilars are approved biologics that have been demonstrated to be highly similar to a reference product.
  • When a biosimilar is approved by the TGA as a clinically comparable version of the reference product, the biosimilar should generally be considered as interchangeable. This means that a patient can expect an equivalent outcome with either treatment with regard to safety and efficacy.
  • The scientific principles for establishing biosimilarity are the same as those for demonstrating comparability after a change in the manufacturing process of an already licensed biological.
  • Structural variances between a biosimilar and the originator are only acceptable within the heterogeneity pattern of the molecule. Any variances need to be explained and justified with regard to the potential impact on clinical performance.
  • Biosimilars have been used safely and effectively in the EU since 2006 and Australia since 2011 with over 1.5m patient days in Australia and 400 million in the EU.

Our Members

Juno
Juno
Sandoz logo
Sandoz logo
Viatris
Viatris
Arrow logo
Arrow logo
apotex
apotex
Celltrion Healthcare
Celltrion Healthcare
Fresnius Kabi
Fresnius Kabi
Fresnius Kabi
generic_partners
generic_partners
southern_cross
southern_cross
commercial_eyes
commercial_eyes
sinapse
sinapse

Generic Medicines: The Facts

Generic Medicines Facts

Generic medicines are quality medicines at affordable prices. Ask your doctor to prescribe a generic medicine, or ask for a generic medicine next time you take your prescription to the pharmacy. … More…

The promise of Biosimilars

Biosimilars

https://youtu.be/sBDur7xa084   Biosimilars provide a unique opportunity to help manage the growing costs of biological medicines on the PBS. They offer therapeutically equivalent and … More…

Patients and economy to benefit from ‘medicine manufacturing’ roadmap

March 2, 2021

2 March 2021 Canberra, ACT Australia’s peak body for affordable medicines, today welcomed the Government’s launch of … More...

Active Ingredient Prescribing – a game changer for patients: Prescription reforms to further support patient safety

February 1, 2021

1 February 2021 Canberra, ACT Canberra: Australia’s patients will be the … More...

Announcement of Independent Chair

December 9, 2020

9 December 2020 Canberra, ACT Global health policy powerhouse, Jane Halton … More…

© 2021 Generic Medicines Industry Association Pty Ltd | Site Map | Contact Us